Full Guidelines
Click here to view article

Tools


Additional Documents
Click here to see additional documents

Endorsements
This Clinical Practice Guideline has been endorsed by the College of Family Physicians of Canada.

Summary of recommendations for clinicians and policy-makers
The CTFPHC will continue to carefully monitor the scientific developments in the prevention and management of obesity and report back to Canadians within 5 years with an update of the 2015 guidelines.
Recommendations
Measurement of BMI
These recommendations apply to apparently healthy adults ≥ 18 years of age who present to primary care. These recommendations do not apply to people with eating disorders, or who are pregnant.
- We recommend measuring height, weight and calculating BMI1 at appropriate2 primary care visits.
(Strong recommendation; very low quality evidence)
Prevention of weight gain
These recommendations do not apply to people with eating disorders, or who are underweight, pregnant, overweight or obese (Body Mass Index [BMI] ≥ 25).
- We recommend that practitioners not offer formal, structured interventions3 aimed at preventing weight gain in normal weight adults.
(Weak recommendation; very low quality evidence)
Management of overweight and obesity
These recommendations apply to adults ≥ 18 years of age who are overweight or obese (25 ≤ BMI < 40). Pregnant women and people with health conditions where weight loss is inappropriate are excluded. These guidelines do not apply to people with BMI ≥ 40, who may benefit from specialized bariatric programs.
- For adults who are obese (30 ≤ BMI < 40) and are at high risk of diabetes4, we recommend that practitioners offer or refer to structured behavioural interventionsiii aimed at weight loss.
(Strong recommendation; moderate quality evidence) - For adults who are overweight or obese, we recommend that practitioners offer or refer to structured behavioural interventions5 aimed at weight loss.
(Weak recommendation; moderate quality evidence) - For adults who are overweight or obese, we recommend that practitioners not routinely offer pharmacologic interventions (orlistat or metformin) aimed at weight loss6.
(Weak recommendation; moderate quality evidence)
Additional Documents
-
Protocol (pdf)
- Prevention Systematic Review (pdf)
- Treatment Systematic Review (pdf)
- Maintenance Supplementary Report (pdf)
- Published Systematic Review
- Prevention List of Excluded Studies (pdf)
- Treatment List of Excluded Studies (pdf)
- CMAJ Author Podcast
- Guideline Presentation

